Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could offer insights into the health of the U.S.
Some results have been hidden because they may be inaccessible to you